The anti-IL-6 receptor antibody, tocilizumab, shows efficacy in inhibiting tumor growth and stemness induced by Tregs in glioma xenograft models60,61 Tregs are subpopulations of CD4+ T cells that suppress the immune response by inhibiting the activation of NK cells and the cytotoxic function of CD8+ T cells62. This evidence concerns the gene CD8A and neoplasm.